These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

98 related items for PubMed ID: 3121244

  • 1. RO23-6240, a new orally absorbed quinolone: in vitro comparison with other broad-spectrum oral antimicrobial agents and imipenem.
    Aldridge KE, Schiro DD, Sanders CV.
    Diagn Microbiol Infect Dis; 1987 May; 7(1):9-19. PubMed ID: 3121244
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Comparative in vitro activity of RO 23-6240 (fleroxacin), a new 4-quinolone derivative.
    Machka K, Braveny I.
    Eur J Clin Microbiol; 1987 Aug; 6(4):482-5. PubMed ID: 3117538
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Emergence of bacterial resistance to imipenem and ciprofloxacin in a university hospital.
    Fass RJ, Barnishan J, Ayers LW.
    J Antimicrob Chemother; 1995 Aug; 36(2):343-53. PubMed ID: 8522464
    [Abstract] [Full Text] [Related]

  • 6. Comparative in-vitro activity of Ro 23-6240, a new trifluorinated quinolone.
    Verbist L.
    J Antimicrob Chemother; 1987 Sep; 20(3):363-72. PubMed ID: 3119552
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. In-vitro activity of fleroxacin compared with three other quinolones.
    Bremner DA, Dickie AS, Singh KP.
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():19-23. PubMed ID: 3144536
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. In vitro activities of a dual-action antibacterial agent, Ro 23-9424, and comparative agents.
    Beskid G, Fallat V, Lipschitz ER, McGarry DH, Cleeland R, Chan K, Keith DD, Unowsky J.
    Antimicrob Agents Chemother; 1989 Jul; 33(7):1072-7. PubMed ID: 2782857
    [Abstract] [Full Text] [Related]

  • 11. In vitro antibacterial activity of imipenem in combination with newer quinolone derivatives.
    Kern W, Gulden H, Vanek E, Kurrle E.
    Chemotherapy; 1988 Jul; 34(2):117-26. PubMed ID: 3164670
    [Abstract] [Full Text] [Related]

  • 12. In vitro susceptibility of nosocomial Pseudomonas aeruginosa, enterobacteriaceae, and staphylococci to ciprofloxacin and ten other broad-spectrum antibiotics.
    Weinstein RA, Nathan C, Delzell D, Kabins SA.
    Chemioterapia; 1987 Oct; 6(5):315-8. PubMed ID: 3123078
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. In vitro studies of fleroxacin (Ro 23-6240), a new trifluorinated quinolone derivative.
    Digranes A, Benonisen E, Salveson A, Zahm F.
    Chemotherapy; 1988 Oct; 34(5):401-10. PubMed ID: 3141116
    [Abstract] [Full Text] [Related]

  • 16. In-vitro and in-vivo antibacterial activity of fleroxacin, a new fluorinated quinolone.
    Aoyama H, Inoue M, Mitsuhashi S.
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():99-114. PubMed ID: 2849604
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. In-vitro activity of fleroxacin.
    Georgopoulos A, Breyer S, Georgopoulos M, Mailer H, Graninger W.
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():25-9. PubMed ID: 3144544
    [Abstract] [Full Text] [Related]

  • 19. In vitro activity of RO 23-6240 (AM-833): a new fluoroquinolone.
    Fass RJ, Helsel VL.
    Diagn Microbiol Infect Dis; 1987 Apr; 6(4):293-9. PubMed ID: 3107872
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.